
Ardelyx (ARDX) Stock Forecast & Price Target
Ardelyx (ARDX) Analyst Ratings
Bulls say
Ardelyx Inc demonstrated significant financial performance with total revenue surpassing consensus expectations by approximately $16 million, attributed in part to an $8 million beat from its IBSRELA product. The company reported a robust 27% quarter-over-quarter growth, excluding one-time benefits, and reiterated its peak U.S. revenue guidance of $750 million before patent expiration. Furthermore, XPHOZAH's U.S. net sales exceeded consensus by around $3 million, indicating early success in the company's strategy to adapt to the changing Medicare Part D coverage landscape.
Bears say
Ardelyx Inc. faces a challenging financial outlook due to the recent loss of Medicare Part D coverage for its product Xphozah, which could significantly impact revenues. Despite efforts to target the non-Medicare patient population, making up approximately 40% of the market, the absence of financial guidance for fiscal year 2025 introduces heightened uncertainty regarding future performance. This combination of coverage challenges and lack of forward guidance creates a precarious situation that may hinder investor confidence in the company's stock.
This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.
Ardelyx (ARDX) Analyst Forecast & Price Prediction
Start investing in Ardelyx (ARDX)
Order type
Buy in
Order amount
Est. shares
0 shares